吉西他滨联合FAM方案化疗对晚期胰腺癌患者的疗效研究  

Effects of Gemcitabine Combined with FAM on Advanced Pancreatic Cancer

作　　者：郭海梅[1] 赵志峰 GUO Hai-mei;ZHAO Zhi-feng(Department of Gastroenterology,the Fourth Affiliated Hospital of China Medical University,Shenyang,Liaoning,110032,China)

机构地区：[1]中国医科大学附属第四医院消化内科,辽宁沈阳110032

出　　处：《中国血液流变学杂志》2019年第4期427-429,共3页Chinese Journal of Hemorheology

摘　　要：目的探讨吉西他滨联合FAM方案治疗晚期胰腺癌的临床疗效.方法回顾性收集2017年1月-2018年12月入院接受治疗的晚期胰腺癌患者62例,其中31例为对照组,接受FAM方案化疗;另外31例为观察组,接受吉西他滨联合FAM方案化疗.每21 d为一个化疗周期,2个周期后进行疗效及不良反应评价,并进行体内相关肿瘤标志物检测.按照RECIST标准进行客观疗效评价,检测并比较各组化疗前后血清癌胚抗原(CEA)、糖链抗原19-9(CA19-9)、糖链抗原125(CA125)水平.采用NCI CTC 3.0标准进行化疗不良反应评价.结果治疗2个周期以后,观察组患者总有效率为61.29%,显著高于对照组总有效率35.48%,差异具有统计学意义(P<0.05).观察组疾病总控制率83.87%,显著高于对照组总控制率58.06%,差异具有统计学意义(P<0.05).化疗后各组患者血清CEA、CA19-9、CA125水平均显著降低,且观察组血清各肿瘤标志物水平显著低于对照组,差异均具有统计学意义(P<0.05).观察组与对照组患者不良反应发生率比较,差异无统计学意义(P>0.05).结论吉西他滨联合FAM方案治疗晚期胰腺癌临床疗效显著,能够提高患者生存质量,不良反应可耐受.Objective To investigate the clinical efect of gemcitabine combined with FAM in the treatment of advanced pancreatic cancer.Methods A retrospective study was conducted to collect 62 patients with advanced pancreatic cancer who were admitted to the Fourth Affiliated Hospital of China Medical University for treatment from January 2017 to December 2018,including 31 patients in the control group who received FAM chemotherapy.The other 31 patients were treated with gemcitabine combined with FAM.Every 21 days was a chemotherapy cycle,and efficacy and adverse reactions were evaluated after 2 cycles,and relevant tumor markers were detected in vivo.Objective efficacy evaluation was performed according to RECIST criteria,and serum carcino-embryonic antigen(CEA),sugar chain antigen 19-9(CA19-9),and sugar chain antigen 125(CA125)levels were detected and compared before and after chemotherapy in each group.The national cancer institute toxicity criteria were used to evaluate the adverse reactions to chemotherapy.Results After 2 cycles of treatment,the total effective rate of patients in the observation group was 61.29%,significantly higher than that in the control group(35.48%),and the difference was statistically significant(P<0.05).The total disease control rate in the observation group was 83.87%,significantly higher than that in the control group(58.06%),and the diference was statistically significant(P<0.05).After chemotherapy,the levels of CEA,CA19-9 and CA125 in each group were significantly decreased,and the levels of tumor markers in the observation group were significantly lower than those in the control group,with statistically significant differences(P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P>0.05).Conclusion Gemcitabine combined with FAM has significant clinical efficacy in the treatment of advanced pancreatic cancer,which can improve the quality of life of patients and the tolerance of adverse reactions.

关 键 词：吉西他滨 FAM方案 胰腺癌 疗效研究 

分 类 号：R735.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]